Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Contineum's Multiple Sclerosis drug missed key goals in a Phase 2 trial as RBC cut its target but highlighted stronger pote...
RBC Capital analyst Brian Abrahams maintains Contineum Therapeutics (NASDAQ:CTNM) with a Outperform and lowers the price tar...
CTNM: -20% | Contineum Therapeutics shares are trading lower after the company announced that topline data from its Phase 2 VIS...
Contineum Therapeutics (NASDAQ:CTNM) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate o...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including...
